Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer

Winston W. Tan, MD; Maurie Markman, MD

August 16, 2022

Patients with KRAS mutations tend to have a poorer prognosis, and KRAS mutations have been identified as negative prognostic biomarkers. Patients with KRAS mutations appear to have a shorter survival than those with wild-type KRAS. However, KRAS mutational status is not predictive of a lack of chemotherapeutic efficacy, according to NCCN guidelines.

A 2018 meta-analysis indicated that EGFR mutations were significantly associated with improved OS and disease-free survival, whereas KRAS mutations predicted worse disease-free survival and OS in patients with resected NSCLC.

Learn more about the clinical significance of KRAS mutations in NSCLC.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Winston W. Tan, Maurie Markman. Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer - Medscape - Aug 16, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: KRAS Mutations in Non-Small Cell Lung Cancer

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Winston W. Tan, MD

Maurie Markman, MD

Comments

Email This

Feedback